Target: Integrin alpha 4 + beta 7
Specificity: Detects human Integrin alpha 4 + beta 7. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Vedolizumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: Vedolizumab, an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. Vedolizumab has an approximate molecular weight of 147 kilodaltons.
Concentration: 1.0 - 5.0 mg/ml
Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.
Purity: >95% by SDS-PAGE and HPLC
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
